Tortugas Neuroscience Launches with Brain Drug Pipeline from Chinese and Japanese Partners
Tortugas Neuroscience launched Tuesday as a new drug company focused on brain disorders. The startup will develop medicines licensed from Chinese drugmaker Jiangsu Hansoh and Japanese pharmaceutical company Eisai.
Tortugas Neuroscience officially launched Tuesday with a mission to develop new treatments for brain and nervous system diseases. The startup is taking a different approach by licensing existing drug candidates from established pharmaceutical companies rather than starting from scratch.
The company has secured licensing deals with two major drugmakers: Jiangsu Hansoh, a Chinese pharmaceutical company, and Eisai, a Japanese pharmaceutical firm. These partnerships give Tortugas access to drug candidates that have already undergone some development.
Tortugas says it focuses on neurological diseases with high unmet medical needs. The company uses what it calls translational approaches to quickly identify whether drugs will work and have real impact for patients.
The startup is backed by Cure Ventures and aims to bridge expertise in neurology and neuropsychiatry. Brain disorders represent one of the most challenging areas in medicine, with high failure rates for new drugs but also enormous potential impact for patients.
Brain disorders like Alzheimer's, depression, and epilepsy affect millions of people but have few effective treatments. New companies entering this space could lead to better drugs for patients who currently have limited options.
Watch for Tortugas to announce which specific brain disorders it will target and when clinical trials might begin.
Was this article helpful?
0 people found this helpful